Oncology evaluation directory Hepato-oncology

Liver Cancer Evaluation

A hepatology-oncology review for liver tumors, separating hepatocellular carcinoma, cholangiocarcinoma and liver metastases while organizing liver function, viral hepatitis status, portal hypertension and previous local or systemic therapy.

Liver functionTumor type clarityViral hepatitis context
Medical disclaimer: This page is informational and coordination-focused. It does not diagnose, prescribe, promise treatment suitability or replace urgent local medical care.
Clinical file logic

What the specialist needs to understand before any treatment discussion.

“Liver cancer” can mean hepatocellular carcinoma, cholangiocarcinoma or metastases from another primary tumor. The file must clarify the origin because treatment logic and risk assessment are very different.

For primary liver cancer, liver function and portal hypertension can be as important as tumor size. The review therefore includes Child-Pugh-type information, bilirubin, albumin, INR, ascites and viral hepatitis context.

01

Tumor origin

HCC, cholangiocarcinoma, mixed tumor or metastasis must be clarified.

02

Liver function

Bilirubin, albumin, INR, platelets, ascites, encephalopathy and cirrhosis status are reviewed.

03

Viral hepatitis

HBV/HCV history, antiviral therapy and viral load when available are included.

04

Tumor distribution

Number/size of lesions, portal vein thrombosis, vascular invasion and extrahepatic spread are documented.

05

Prior treatment

Surgery, ablation, TACE/TARE, radiation, immunotherapy/targeted therapy or chemotherapy are summarized.

06

Current safety

Jaundice, ascites, infection, bleeding risk and performance status are documented.

Evaluation matrix

How the case is reviewed without reducing it to a diagnosis name.

Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.

01

Origin determines route

Primary liver cancer and liver metastases are not managed as the same diagnosis.

02

Liver reserve

Treatment feasibility can be limited by liver function even when tumor burden looks treatable.

03

Vascular invasion

Portal vein thrombosis or vascular invasion changes specialist interpretation.

04

Hepatitis context

HBV/HCV control and liver inflammation affect safety planning.

Documents to prepare

A complete medical file prevents delay and unrealistic expectations.

Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.

Diagnosis recordsPathology if available, imaging-based HCC diagnosis details or primary cancer records for metastases.
Liver imagingTriphasic CT/MRI, PET/CT when relevant and reports describing vascular invasion.
Liver labsBilirubin, albumin, INR, AST/ALT, platelets, creatinine and AFP/CA19-9 when used.
Hepatitis recordsHBV/HCV tests, viral load and antiviral treatment details.
Treatment historyAblation, TACE/TARE, surgery, radiation and systemic therapy timeline.
Current clinical statusAscites, encephalopathy, bleeding, nutrition and performance status.
Cuba context

How Cuba-related options are framed responsibly.

The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.

01

Hepatology and oncology overlap

The review may require both liver function assessment and cancer treatment review.

02

Safety constraints are central

Poor liver reserve or active complications can limit travel or treatment options.

03

No diagnosis assumptions

The file does not assume all liver lesions are primary liver cancer.

When local care comes first

Do not wait for international review if urgent symptoms are present.

International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.

  • Vomiting blood, black stool, severe abdominal swelling or confusion.
  • Fever with jaundice, severe abdominal pain or suspected infection.
  • Rapidly worsening jaundice, kidney function decline or severe weakness.
Coordination pathway

From records to written next steps.

  1. File intakeReports, imaging, summaries and current symptoms are uploaded through the application flow.
  2. Quality checkThe coordination team checks readability, dates, translation needs and missing items.
  3. Specialist routingThe case is prepared around a clear medical question and routed to the relevant review pathway.
  4. Written responseThe patient receives an organized next-step explanation before travel, payment or treatment logistics are considered.
Questions

Before starting the application.

Does this page mean I am suitable for a Cuba-based treatment?

No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.

Can I send only a short summary?

A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.

Will the coordinator choose my treatment?

No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.

What happens if my file is incomplete?

The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.

Can urgent symptoms be handled through this page?

No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.

Start with the file

Submit documents before making a travel or treatment decision.

A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.